Hepatitis B virus pre-existing drug resistant mutation is related to the genotype and disease progression

HBV pre-existing drug resistant mutation

  • Liping Wang Qilu Hospital of Shandong University, Shandong, China
  • Fangzheng Han Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
  • Hualing Duan Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
  • Fang Ji Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
  • Xuebing Yan Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
  • Yuchen Fan Qilu Hospital of Shandong University, Shandong, China
  • Kai Wang Qilu Hospital of Shandong University, Shandong, China

Abstract

Introduction: Previous studies have indicated that the drug-resistant mutations of hepatitis B virus (HBV) are a major obstacle to antiviral therapy. However, it is still unclear whether there are pre-existent resistance mutations in patients with HBV infection and the relationship between drug-resistant mutation, genotypes, and progression of hepatitis B disease.


Methodology: A total of 357 treatment-naïve patients with HBV infection were involved in this retrospective study. The drug-resistant mutations of HBV reverse transcriptase domain were screened by direct gene sequencing.


Results: Lamivudine (LAM) resistance was detected in 8 patients (3.7%) with chronic hepatitis B (CHB), 13 (11.7%) patients with liver cirrhosis (LC), and 6 (21.4%) patients with hepatocellular carcinoma (HCC). Adefovir(ADV)-resistant mutations were detected in 10 (4.6%) patients with CHB, 15 (13.5%) patients with  LC and 4 (14.5%) patients with HCC. Both LAM and ADV resistant mutations were detected in 2 patients (0.9%) with CHB, 1 patient (0.9%) with LC and 1 patient (3.6%) with HCC. Significant differences (p <0.01) were observed in the drug-resistance rates among patients with CHB, LC and HCC. Meanwhile, all the drug-resistant mutations were found in patients with HBV genotype C.


Conclusions: This study demonstrated higher risk of pre-existing drug-resistant mutations in patients with HBV genotype C comparing to patients with HBV genotype B. Likewise, increasing prevalence of pre-existing drug-resistant mutations was shown, alongside with the progression of the disease.

Author Biographies

Liping Wang, Qilu Hospital of Shandong University, Shandong, China

Department of Hepatology,

Department of Infectious Diseases

 

Fangzheng Han, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Department of Infectious Diseases

Hualing Duan, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Department of Infectious Diseases

Fang Ji, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Department of Infectious Diseases

Xuebing Yan, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

Department of Infectious Diseases

Yuchen Fan, Qilu Hospital of Shandong University, Shandong, China

Department of Hepatology

Kai Wang, Qilu Hospital of Shandong University, Shandong, China

Department of Hepatology

Published
2017-10-07
How to Cite
Wang L, Han F, Duan H, Ji F, Yan X, Fan Y, Wang K (2017) Hepatitis B virus pre-existing drug resistant mutation is related to the genotype and disease progression. The Journal Of Infection In Developing Countries 11 (09): 727-732. https://doi.org/10.3855/jidc.9021
Section
Brief Original Articles

Keywords

hepatitis B virus; pre-existing drug resistance; mutation; reverse transcriptase